Amyloid β-peptide(1-42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain

Brain Pathology

Volumn 14, Issue 4, 2004, Pages 426-432

  Butterfield, D Allan ^a,b   Boyd Kimball, Debra ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; METHIONINE; METHIONINE 35; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CONFERENCE PAPER; DERIVATIZATION; HUMAN; LIPID PEROXIDATION; MICHAEL ADDITION; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEOMICS;

EID: 8744276616     PISSN: 10156305     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2004.tb00087.x     Document Type: Conference Paper

References (62)

1. Aksenov MY, Aksenova MV, Butterfield DA, Markesbery WR (2000) Oxidative modification of creatine kinase BB in Alzheimer's disease brain. J Neurochem 74:2520-2527.
2. Barnham KJ, Ciccotosto GD, Tickler AK, Ali FE, Smith DG, Williamson NA, Lam YH, Carrington D, Tew D, Kocak G, Volitakis I, Separovic F, Barrow CJ, Wade JD, Masters CL, Cherny RA, Curtain CC, Bush AI, Cappai R (2003) Neurotoxic, Redox-competent Alzheimer's β-amyloid is released from lipid membrane by methionine oxidation. J Biol Chem 278:42959-42965.
3. Blass JP, Gibson GE (1991) The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease. Rev Neurol 147:513-525.
4. 1-42: involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide. Neurobiol Aging 25:563-568.
5. Butterfield DA, Lauderback CM (2002) Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Rad Biol Med 32:1050-1060.
6. Butterfield DA, Stadtman ER (1997) Protein oxidation processes in aging brain. Adv Cell Aging Gerontol 2:161-191.
7. Butterfield DA, Boyd-Kimball D, Castegna A (2003) Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration. J Neurochem 86:1313-1327.
8. Butterfield DA, Drake J, Pocernich C, Castegna A (2001) Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 7:548-554.
9. 1-42-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic Res 36:1307-1313.
10. 1-42-associated free radical-induced oxidative stress and neurodegeneration in Alzheimer's disease brain: mechanisms and consequences. Curr Med Chem 10:2651-2659.
11. Butterfield DA (2004) Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain. Brain Res 1000:1-7.
12. Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Marksbery WR, Butterfield DA (2002) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain part I: creatine kinase BB, glutamine synthetase, and ubiquitin carboxy-terminal hydrolase L-1. Free Rad Biol Med 33:562-571.
13. Castegna A, Aksnov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA (2002) Proteomics identification of oxidatively modified proteins in Alzheimer's disease brain part II: dihydropyrimidinase related protein II, a-enolase, and heat schock cognate 71. J Neurochem 82:1524-1532.
14. Castegna A, Lauderback CM, Mohmmad-Abdul H, Butterfield DA (2004) Modulation of phospholipid asymmetry in synaptosomal membranes by the lipid peroxidation products, 4-hydroxynonenal and acrolein: implications for Alzheimer's disease. Brain Res 1004:193-197.
15. Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA (2003) Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem 85:1394-1401.
16. Coleman PD, Flood DG (1987) Neuron numbers and dendritic extent in normal aging and Alzheimer's disease. Neurobiol Aging 8:521-545.
17. Dong J, Atwood CS, Anderson VE, Siedlak SL, Smith MA, Perry G, Carey PR (2003) Metal binding and oxidation of Amyloid-β within isolated senile plaque cores: raman microscopic evidence. Biochemistry 42:2768-2773.
18. 1-42 in a transgenic Caenorhabditis elegans model. Neurobiol Aging 24:415-420.
19. Drake J, Petroze R, Castegna A, Ding Q, Keller JN, Markesbery WR, Lovell MA, Butterfield DA (2004) 4-Hydroxynonenal oxidatively modifies histones: implications for Alzheimer's disease. Neurosci Letts 356:155-158.
20. Drake J, Sultana R, Aksenova M, Calabrese V, Butterfield DA (2003) Elevation of mitochondrial glutathione by gamma-glutamylcysteine ethyl ester protects mitochondria against peroxynitrite-induced oxidative stress. J Neurosci Res 74:917-927.
21. Drake J, Kanski J, Varadarajan S, Tsoras M, Butterfield DA (2002) Elevation of brain glutathione by g-glutamylcysteine ethyl ester protects against peroxynitrite-induced oxidative stress. J Neurosci Res 68:776-784.
22. Esterbauer H, Schaur RJ, Zollner H (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11:81-128.
23. Giacobini E (2003) Cholinergic function and Alzheimer's disease. Int J Geriatr Psychiatry 18:S1-S5.
24. Good PF, Werner P, Hsu A, Olanow C, Perl DP (1996) Evidence for neuronal oxidative damage in Alzheimer's disease. Am J Pathol 149:21-27.
25. Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M, Aksenova M, Gabbita P, Wu JF, Carney JM, Lovell M, Markebery WR, Butterfield DA (1995) Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 65:2146-2156.
26. 1,42 peptide of Alzheimer's disease. J Biol Chem 277:40173-40176.
27. Kanski J, Aksenova M, Butterfield DA (2002) Substitution of isoleucine-31 by helical-breaking proline abolishes oxidative and neurotoxic properties of Alzheimer's amyloid beta-peptide. Free Radic Biol Med 32:1205-1211.
28. Katzman R, Saitoh T (1991) Advances in Alzheimer's disease. FASEB J 5:278-86.
29. Keller JN, Hanni KB, Markesbery WM (2000) Impaired proteasome function in Alzheimer's disease. J Neurochem 75:436-439.
30. Koppal T, Drake J, Yatin S, Jordan B, Varadarajan S, Bettenhausen L, Butterfield, DA (1999) Peroxynitrite-induced alterations in synaptosomal membrane proteins: insight into oxidative stress in Alzheimer's Disease. J Neurochem 72:310-317.
31. Kou YM, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC, Kalback WM, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Roher AE (2001) Comparative analysis of amyloid-β chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J Biol Chem 276:12991-12998.
32. 1-42. J Neurochem 78:413-416.
33. Lovell MA, Xie C, Markesbery WR (2001) Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging 22:187-194.
34. Lubec G, Nonaka M, Krapfenbauer K, Gratzer M, Cairns N, Fountoulakis M (1999) Expression of the dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimer's disease brain is downregulated at the mRNA and dysregulated at the protein level. J Neural Transm Suppl 57:161-177.
35. Mark RJ, Lovell MA, Markesberry WR, Uchida K Mattson MP (1997) A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid β-peptide. J Neurochem 68: 255-264.
36. Markesbery MR (1997) Oxidative Stress Hypothesis in Alzheimer's disease. Free Radic Biol Med 23:134-147.
37. Markesbery WR, Lovell MA (1998) Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19:33-36.
38. Masliah E, Alford M, De Teresa R, Mallory M, Hansen L (1995) Deficient glutamate transport is associtated with neurodegeneration in Alzheimer's disease. Ann Neurol 40:759-766.
39. Naslund J, Schierhorn A, Hellman U, Lannfelt L, Roses AD, Tjernberg LO, Silberring J, Gandy SE, Winblad B, Greengard P, Nordstedt C, Terenius L (1994) Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal aging. Proc Nat Acad Sci U S A 91: 8378-8382.
40. Ojika K, Tsugu Y, Mitake S, Otsuka Y, Takada E (1998) NMDA receptor activation enhances the release of a cholinergic differentiation peptide (HCNP) from hippocampal neurons in vitro. Neuroscience 101:341-352.
41. Pocernich CB, and Butterfield DA (2003) Acrolien inhibits NADH-linked mitochondrial enzyme activity: implications for Alzheimer's disease. Neurotox Res 5:515-520.
42. Pogocki D, and Schöneich C (2002) Redox properties of Met35 in neurotoxic b-amyloid peptide. A molecular modeling study. Chem Res Toxicol 15:408-418.
43. ox. Eur J Biochem 268: 5930-5936.
44. Rosser MN, Svendsen C, Hunt SP, Mountjoy CQ, Roth M, Iversen LL (1982) The substantia innominata in Alzheimer's disease: a histochemical and biochemical study of cholinergic marker enzymers. Neurosci Lett 28:217-222.
45. Scheltens P, Korf ESC (2000) Contribution of neuroimaging in the diagnosis of Alzheimer's disease and other dementias. Curr Opin Neuro 13:391-396.
46. Schonberger SJ, Edgar PF, Kydd R, Faull RLM, Cooper GJS (2001) Proteomic analysis of the brain in Alzheimer's disease: Molecular phenotype of a complex disease process. Proteomics 1:1519-1528.
47. Schöneich C, Pogocki D, Hug GL, Bobrowski K (2003) Free radical reactions of methionine in peptides: mechanisms relevant to beta-amyloid oxidation and Alzheimer's disease. J Am Chem Soc 125:13700-13713.
48. Seilheimer B, Bohrmann B, Bondolfi L, Müller F, Stüber D, Dübeli H (1997) The toxicity of the Alzheimer's β-amyloid peptide correlated with a distinct fiber morphology. J Struct Biol 119:59-71.
49. Selkoe DJ (2001) Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 3:75-80.
50. Shringarpure R, Grune T, Davies KJ (2001) Protein oxidation and 20S proteasome-dependent proteolysis in mammalian cells. Cell Mol Life Sci 58:1442-1450.
51. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G (1997) Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 17:2653-2657.
52. Subbarao KV, Richardson JS, Ang LC (1990) Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J Neurochem 55: 342-345.
53. Subramaniam R, Roediger F, Jordan B, Mattson MP, Keller JN, Waeg G, Butterfield DA (1997) The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins. J Neurochem 69:1161-1169.
54. 1-42-induced oxidative stress in primary neuronal cells. Free Rad Res 38:449-458.
55. Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C (1999) Alterations of 3-nityrosine concentration in the cerebrospinal fluid during aging and in patients with Alzheimer's disease. Neurosci Letts 269:52-54.
56. Tsuji T, Shiozaki A, Kohno R, Yoshizato K, Shimohama S (2002) Proteomic profiling and neurodegeneration in Alzheimer's disease. Neurochem Res 27:1245-1253.
57. Uchida K (2003) 4-Hydroxynonenal: a product and mediator of oxidative stress. Prog Lipid Res 42:318-343.
58. 1-42 and Aβ(25-35). J Am Chem Soc 123:5625-5631.
59. Varadarajan S, Yatin S, Aksenova M, Butterfield DA (2000) Review: Alzheimer's Amyloid β-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol 130:184-208.
60. Yatin SM, Aksenov M, Butterfield DA (1999) The antioxidant vitamin E modulated amyloid β-peptide-induced creatine kinase activity inhibition and increased protein oxidation: implications for the free radical hypothesis of Alzheimer's disease. Neurochem Res 24:427-435.
61. 1-42-induced neuronal protein oxidation and reactive oxygen species Production. J Alzheimer's Dis 2:123-131.
62. 1-42. Neurobiol Aging 20:325-330.